Genes, compositions, kits, and methods for identification,...

Details Genes, compositions, kits, and methods for identification,... Genes, compositions, kits, and methods for identification,...

2010-06-14

2011-11-22

Rawlings, Stephen (Department: 1643)

Chemistry: analytical and immunological testing

Cancer

C435S006120, C435S007100, C435S007230, C530S350000, C530S387700, C536S023500, C536S024300

Reexamination Certificate

active

08062892

ABSTRACT:
The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.

REFERENCES:
patent: 2002/0086354 (2002-07-01), Holtzman et al.
patent: 2002/0169284 (2002-11-01), Ashkenazi et al.
patent: 2002/0177553 (2002-11-01), Ashkenazi et al.
patent: 2002/0192706 (2002-12-01), Ashkenazi et al.
patent: 2003/0008352 (2003-01-01), Baker et al.
patent: 2003/0008353 (2003-01-01), Baker et al.
patent: 2003/0013153 (2003-01-01), Baker et al.
patent: 2003/0049738 (2003-03-01), Baker et al.
patent: 2003/0175754 (2003-09-01), Murry et al.
patent: 2007/0172830 (2007-07-01), Ruben et al.
patent: 1167387 (2002-01-01), None
patent: 2000-32984 (2000-02-01), None
patent: WO-99/07850 (1999-02-01), None
patent: WO-99/07893 (1999-02-01), None
patent: WO-99/35158 (1999-07-01), None
patent: WO-99/46281 (1999-09-01), None
patent: WO-99/58660 (1999-11-01), None
patent: WO-00/53756 (2000-09-01), None
patent: WO-01/42451 (2001-06-01), None
patent: WO-01/54708 (2001-08-01), None
patent: WO-01/68848 (2001-09-01), None
patent: WO-01/87917 (2001-11-01), None
patent: WO-02/057414 (2002-07-01), None
patent: WO-02/068649 (2002-09-01), None
Ahmed, N., et al. “Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.”Carcinogenesis. Feb. 2000; 23(2):237-44.
Bates, R.C., et al. “Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.”J Clin Invest. Feb. 2005; 115(2):339-47.
Bossinakou, K.S., et al. “L-dopa decarboxylase mRNA levels are correlated with the L-dopa decarboxylase protein profile during the development of the insectCeratitis capitata.” Insect Biochem. Molec. Biol. 1996; 26(8-9):859-65.
Breuss, J.M., et al. “Restricted distribution of integrin β6 mRNA in primate epithelial tissues.”J Histochem Cytochem. Oct. 1993; 41(10):1521-7.
Breuss, J.M., et al. “Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling.”J Cell Sci. Jun. 1995; 108:2241-51.
Chen, G., et al. “Discordant protein and mRNA expression in lung adenocarcinomas.”Mol Cell Proteomics. Apr. 2002; 1(4):304-13.
Chen, Y., et al. “Identification of cervical cancer markers by cDNA and tissue microarrays.”Cancer Res. Apr. 15, 2003; 63(8):1927-35.
Cheng, Q., et al. “Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix.”Br J Cancer. Jan. 21, 2002; 86(2):274-81.
Critchfield, G.C. “The future of DNA diagnostics.”Dis Markers. Oct. 1999; 15(1-3):108-11.
Hamidi, S., et al. “Expression of αvβ6integrin in oral leukoplakia.”Br J Cancer. Apr. 2000; 82(8):1433-40.
Niu, J., et al. “Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the β6 integrin subunit.”Int J Cancer. Jun. 1, 2002; 99(4):529-37.
Rae, F.K., et al. “Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display.”Int J Cancer. Dec. 1, 2000; 88(5):726-32.
Regezi, J.A., et al. “Tenascin and β6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas.”Oral Oncol. Jun. 2002; 38(4):332-6.
Sheppard, D., et al. “Complete amino acid sequence of a novel integrin β subunit (β6) identified in epithelial cells using the polymerase chain reaction.”J Biol Chem. Jul. 15, 1990; 265(20):11502-7.
Sidransky, D. “Nucleic acid-based methods for the detection of cancer.”Science. Nov. 7, 1997; 278(5340):1054-9.
Tockman, M.S., et al. “Considerations in bringing a cancer biomarker to clinical application.”Cancer Res. May 1, 1992; 52(9 Suppl):2711s-18s.
Ward, A.M. “4. Tumour markers.”Immunological Aspects of Cancer(Developments in oncology). B.W. Hancock, et al., Eds. Nov. 1, 1984; 91-106.
Watanabe, M., et al. “Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver.”J Pharmacol Sci. Apr. 2004; 94(4):459-62.
Xue, H., et al. “Role of the αvβ6 integrin in human oral squamous cell carcinoma growth in vivo and in vitro.”Biochem Biophys Res Commun. Nov. 2, 2001; 288(3):610-8.
Ljubimov, Alexander V. et al, “Increased Expression of Tenascin-C-binding Epithelial Integrins in Human Bullous Keratopathy Corneas,”The Journal of Histochemistry&Cytochemistry, vol. 49(11):1341-1350 (2001).
GenBank AC NP—066924, Zimmerli, S.C. et al., “Human epidermal langerhans cells express the tight junction protein claudin-1 and are present in human genetic claudin-1 deficiency (NISCH syndrome),”Exp. Dermatol., vol. 17(1):20-23 (2008) Feb. 17, 2008.

Affiliated with

Also associated with

Rating

Genes, compositions, kits, and methods for identification,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genes, compositions, kits, and methods for identification,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genes, compositions, kits, and methods for identification,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4280785